Home » Stocks » Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. (SUPN)

Stock Price: $23.29 USD 0.21 (0.91%)
Updated Aug 10, 2020 2:10 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.22B
Revenue (ttm) 402.26M
Net Income (ttm) 116.23M
Shares Out 52.54M
EPS (ttm) 2.16
PE Ratio 10.78
Forward PE 21.28
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $23.29
Previous Close $23.08
Change ($) 0.21
Change (%) 0.91%
Day's Open 23.25
Day's Range 23.02 - 23.71
Day's Volume 166,668
52-Week Range 13.12 - 29.81

More Stats

Market Cap 1.22B
Enterprise Value 1.20B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.54M
Float 47.65M
EPS (basic) 2.21
EPS (diluted) 2.16
FCF / Share 2.17
Dividend n/a
Dividend Yield n/a
Earnings Yield 9.27%
FCF Yield 9.32%
Payout Ratio n/a
Shares Short 4.46M
Short Ratio 8.83
Short % of Float 12.97%
Beta 1.55
PE Ratio 10.78
Forward PE 21.28
P/FCF Ratio 10.73
PS Ratio 3.04
PB Ratio 1.99
Revenue 402.26M
Operating Income 152.16M
Net Income 116.23M
Free Cash Flow 114.00M
Net Cash 20.84M
Net Cash / Share 0.40
Gross Margin 93.50%
Operating Margin 37.83%
Profit Margin 28.90%
FCF Margin 28.34%
ROA 8.59%
ROE 21.26%
ROIC 15.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$29.00*
(24.52% upside)
Low
24.0
Current: $23.29
High
33.0
Target: 29.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue39340930221514792.6812.021.480.800.11
Revenue Growth-3.95%35.29%40.57%45.8%59.12%671.1%712.09%84.31%657.55%-
Gross Profit37639428720313986.9210.921.480.800.11
Operating Income14914499.5454.2220.84-5.28-61.92-42.17-37.75-40.12
Net Income11311157.2891.2213.94-10.93-92.27-46.2853.82-38.46
Shares Outstanding52.4151.9950.7649.4747.4942.2631.8517.441.611.59
Earnings Per Share2.102.051.081.760.28-0.26-2.90-2.7231.39-26.38
EPS Growth2.44%89.81%-38.64%528.57%------
Operating Cash Flow14312911566.8134.52-24.50-57.95-47.20-36.19-32.54
Capital Expenditures-2.74-0.84-2.03-1.60-2.10-0.59-1.65-0.75-0.69-0.29
Free Cash Flow14012811365.2132.42-25.09-59.60-47.95-36.87-32.84
Cash & Equivalents34735614090.1262.1974.3482.1988.5148.7932.97
Total Debt376329-4.177.0926.2234.3922.9029.49-
Net Cash / Debt-28.5426.5614085.9655.1148.1147.8065.6119.3032.97
Assets1,16097842431018913711193.9953.7347.01
Liabilities56552515711810196.0977.5336.4244.2991.33
Book Value59545326719288.0140.7033.4657.579.44-44.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Supernus Pharmaceuticals, Inc.
Country United States
Employees 464
CEO Jack A. Khattar

Stock Information

Ticker Symbol SUPN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: SUPN
IPO Date May 1, 2012

Description

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.